Results
142 (64.5%) returned the survey. 25% of respondents wereuncomfortable or very uncomfortable deciding when to endresuscitation. About 20% of respondents reported low levels ofcomfort in performing the other domains. For each of the domainsphysicians had the highest level of comfort, closely followed by RTson night shift. After controlling for other variables in the model,6 years or more experience in the NICU was positively associatedwith comfort in performing and also ending the resuscitation. All staffindicated a need for training and practicing teamwork and alsoinfrequently used procedures and devices.
Conclusions
Additional training in team work and infrequently used proce-dures may be helpful to improve comfort levels in as many as 20% ofprofessionals in the NICU.
doi:10.1016/j.earlhumdev.2010.09.018
AO-11. Ambroxol for antepartum stimulation of neonatallung maturity
Boris Marinov, Nelly Jekova, Andriana Andreeva, Kalina MilanovaDepartment of Perinatology at The University Maternity Hospital“Maichin Dom”, Sofia, Bulgaria
Aim
In the last few decades efforts have beenmade to enhance the fetallung maturity by means of drugs administered to the mother. Themultiple side effects of glucocorticoids have raised the need to look forother ways for prevention of the neonatal respiratory distresssyndrome (NRDS) in the preterm infant. Recent investigationsconsider Ambroxol to be capable of accelerating the fetal lungmaturation as it was shown to stimulate the synthesis and the releaseof pulmonary surfactant by type II pneumocytes. The aim of ourprospective study was to assess the effect of Ambroxol, givenprenatally, on the rate and severity of the NRDS in the preterm infants.
Materials and methods
Twenty-seven pregnant women between 27 and 32 weeks withpreterm labor and their 27 prematurely born infants were entered inthe study. Fifteen of the women were randomised to receiveAmbroxol prenatally (study group) and 12 women did not receiveany medication for acceleration of fetal lung maturity (controlgroup). Ambroxol was given orally in a daily dose of 60 mg (30 ml)every 12 h for seven to ten days depending on the gestational age.The newborn infants were clinically and radiologically assessed fordevelopment and severity of NRDS and were treated according to theEuropean Consensus guidelines on management of NRDS—2007Update.
Results
Severe NRDS occurred in 2 infants (14%) from the study groupcompared to 5 (41%) in the control group. All of them had multiplesurfactant doses andwere ventilated formore than 72 h. The remaining7 infants (59%) from the control group needed at least one dose ofsurfactant and artificial ventilation in the following three days. Nine(60%) of the infants in the study group had mild NRDS treated by nasalCPAP and 4 (26%) had no signs of respiratory distress syndrome.
Conclusions
These results suggest that Ambroxol can reduce the incidence andseverity of NRDS in the premature infants.
doi:10.1016/j.earlhumdev.2010.09.019
AO-12. Our first experiences using Retcam Shuttle inophthalmological examinations
Vadnay AkosDEOECDebrecen University of Medicine and Health Care Sciences, Hungary
Aim
We are using a Retcam Shuttle type video recording equipmentfrom October of 2009 in NICU of DEOEC. Our aim is to report thisinstrument.
Materials and methods
We use the Retcam's mobility in two NICUs of DEOEC and in theDepartment of Ophthalmology for screening retinopathy of prema-turity and other diseases. We are going to show its usability in thispresentation and our first experiences illustrated with pictures.
Results
We examined 322 patients with this instrument, and we treated31 of them with laser photocoagulation from 2009 October to 2010July. Over 200 students have learnt ophthalmology in this periodpartially from its pictures.
Conclusions
We can declare that the instrument is easy to use making widefield, high density pictures of the fundus of the eye, which is veryuseful in following and judging the therapy of borderline cases ofretinopathy of prematurity, it is definitive in teaching, fulfills theprofessional standards, helps a lot in informing the patient's relatives,and gives an ability to archive.
doi:10.1016/j.earlhumdev.2010.09.020
AO-13. Recombinant erythropoietin for neuro-protection in smallpreterm infants: Our experience
Aspazija Sofijanova, Aleksandar Sajkovski, Liljana Kojich,Silvana Naunova-Timovska, Radica Muratovska-DelimitovaDepartment of Neonatal Intensive Care Unit, University Children Hospital,Skopje, Republic of Macedonia
Aim
During the past decade, recombinant human Epo (rhEpo) hasbeen widely used in preterm infants to prevent/treat anemia ofprematurity. EPO was considered not capable of passing throughblood-brain-barrier at low dose. Evidence from animal experimentsreveals that rhEpo must be given in high doses at the beginning orwithin a short (up to 6 h) critical time period after the onset of braininjury to achieve a significant neuro-protective effect.
Abstracts S5
